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Abstract
Background: Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease dementia (PDD), and
frontotemporal lobar dementia (FTLD) are characterized by progressive neuronal loss but differ in their underlying
pathological mechanisms. However, neuroinflammation is commonly observed within these different forms of dementia.
Recently, it has been suggested that an altered sphingolipid metabolism may contribute to the pathogenesis of a variety of
neurodegenerative conditions. Especially ceramide, the precursor of all complex sphingolipids, is thought to be associated
with pro-apoptotic cellular processes, thereby propagating neurodegeneration and neuroinflammation, although it remains
unclear to what extent. The current pathological study therefore investigates whether increased levels of ceramide are
associated with the degree of neuroinflammation in various neurodegenerative disorders.
Methods: Immunohistochemistry was performed on human post-mortem tissue of PDD and FTLD Pick’s disease cases,
which are well-characterized cases of dementia subtypes differing in their neuroinflammatory status, to assess the expression
and localization of ceramide, acid sphingomyelinase, and ceramide synthase 2 and 5. In addition, we determined the
concentration of sphingosine, sphingosine-1-phosphate (S1P), and ceramide species differing in their chain-length in brain
homogenates of the post-mortem tissue using HPLC-MS/MS.
Results: Our immunohistochemical analysis reveals that neuroinflammation is associated with increased ceramide levels in
astrocytes in FTLD Pick’s disease. Moreover, the observed increase in ceramide in astrocytes correlates with the expression
of ceramide synthase 5. In addition, HPLC-MS/MS analysis shows a shift in ceramide species under neuroinflammatory
conditions, favoring pro-apoptotic ceramide.
Conclusions: Together, these findings suggest that detected increased levels of pro-apoptotic ceramide might be a
common denominator of neuroinflammation in different neurodegenerative diseases.
Keywords: Neuroinflammation, Neurodegenerative diseases, Sphingolipids, Ceramide, Ceramide synthase, Acid
sphingomyelinase
Background
Neurodegenerative diseases are characterized by a progres-
sive loss of neuronal integrity and function, followed by
neuronal death. The consequential loss of neuronal cells
negatively affects numerous functions controlled by the
central nervous system (CNS), such as mobility, coordin-
ation, memory, and learning, depending on the location of
the area affected [1, 2]. The major neurodegenerative disor-
ders, like Alzheimer’s disease (AD), Parkinson’s disease
(PD), and frontotemporal lobar dementia (FTLD), differ in
the type of neurons that are affected and the nature of the
accumulated proteins that propagate neurodegeneration.
Therefore, the term neurodegenerative disease comprises a
wide range of conditions varying in underlying cause and
localization of the neuronal loss [3]. However, a common
denominator of such devastating disorders is neuroinflam-
mation, which is increasingly recognized as a key player in
the pathogenesis of several neurodegenerative diseases [4].
Neuroinflammation describes the reactive morphology
and altered function of the glial compartment and in-
volves predominantly astrocytes and microglia [5]. Dur-
ing disease or injury, activated glial cells serve as both
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source and target of proinflammatory mediators, such as
cytokines, chemokines, and reactive oxygen species. Nu-
merous neurodegenerative diseases are associated with
activated glial cells, but the inflammatory reaction is not
distinguishable between the different diseases, despite
the varying underlying causes [6–8]. Therefore, although
the observed inflammatory glial response is presumed to
be secondary to neuronal death or dysfunction, it is
suggested that the activation of microglia and astrocytes
contributes to the progression of the different neurode-
generative diseases. Hence, understanding the under-
lying mechanisms involved in neuroinflammatory
processes may reveal new molecular targets for future
therapy [9–11].
Accumulating evidence suggests that a deregulated
sphingolipid metabolism is associated with a number of
neurodegenerative diseases [12–15]. In general, sphingo-
lipids are highly enriched in the brain and are essential
for the development and maintenance of the functional
integrity of the nervous system [16]. The sphingolipid
metabolism consists of a complex network of highly reg-
ulated pathways producing bioactive lipids that include
ceramide, sphingosine, and sphingosine 1-phosphate
(S1P). In most cell types, ceramide and S1P exert ad-
verse effects on cell survival, where primarily ceramide
is implicated in promoting cellular stress and cell death
[17, 18]. For instance, several studies have shown that
increased levels of ceramide are implicated in the induc-
tion of neural cell death, oxidative stress, and proinflam-
matory gene expression [19, 20]. Therefore, maintaining
a strict sphingolipid balance is of key importance for
cellular survival.
Ceramide synthesis occurs via three different pathways;
the salvage pathway, the sphingomyelinase pathway, and
the de novo pathway [21, 22]. In the salvage pathway,
complex sphingolipids are catabolized into sphingosine
which can then be reused to produce ceramide [23]. In
addition, ceramide can also be generated from the hy-
drolysis of sphingomyelin through the action of sphingo-
myelinases, which exist in two subtypes, namely neutral
sphingomyelinase (nSMase) and acid sphingomyelinase
(ASM) [24, 25]. Finally, in the human brain, five different
ceramide synthase (CerS1, 2, 4, 5, and 6) enzymes
synthesize ceramide in the de novo pathway. These
enzymes preferentially use a relatively restricted subset of
fatty acyl CoAs resulting in the synthesis of ceramides
with different acyl chain lengths [26–28]. Both de novo
synthesis of ceramide as well as the recycling of sphingo-
sine into ceramide in the salvage pathway are controlled
by CerS enzymes. Interestingly, the SM hydrolysis and the
de novo synthesis pathway have been implicated in the
production of pro-apoptotic ceramides [29–31].
We previously reported evidence indicating a role for
a deregulated sphingolipid balance in the pathogenesis
of AD with capillary cerebral amyloid angiopathy [32].
Specifically, we revealed that activated glial cells showed
increased levels of sphingolipids that are associated with
the neuroinflammatory process. Moreover, a shift in the
production of the different ceramide species was ob-
served, favoring long-chain ceramides that are involved
in apoptosis. Therefore, based on our recent findings, we
hypothesize that a deregulated sphingolipid metabolism,
specifically related to an increase in pro-apoptotic cera-
mides, contributes to the observed neuroinflammatory
process in a wide range of neurodegenerative diseases.
To test this hypothesis, we set out to investigate the ex-
pression levels of the enzymes involved in ceramide syn-
thesis and levels of ceramide itself in different
neurodegenerative diseases, which differ in their inflam-
matory status. For this, we selected the inferior frontal
gyrus of well-characterized patients with frontotemporal
dementia Pick’s disease (FTD-Pi) and patients with
Parkinson’s disease with dementia (PDD) since these are
frequent forms of dementia.
Materials and methods
Post-mortem human brain tissue
Post-mortem human brain tissue was obtained from the
Netherlands Brain Bank (NBB), Netherlands Institute for
Neuroscience, Amsterdam. For this study, we selected
the inferior frontal gyrus of five PDD patients, five
FTD-Pi patients, and five age-matched non-demented
controls. All material has been collected from donors
after written informed consent for brain autopsy and use
of brain tissue and clinical information for research pur-
poses. Age, gender, post-mortem delay (PMD), Braak lb,
and cause of death of all cases used in this study are
listed in Table 1.
Immunohistochemistry
Immunohistochemistry was performed as described previ-
ously [32]. In brief, 5 μm cryosections mounted on coated
glass slides (Menzel Gläser Superfrost PLUS, Thermo Scien-
tific, Braunschweig Germany) were air-dried and fixed in
acetone for 10 min. Fixating the tissue with PFA or methanol
resulted in a higher background and a more patchy staining
of astrocytes, confirming the use of acetone as fixative (Add-
itional file 1). Next, the sections were incubated overnight at
4 °C with primary antibodies against ASM, ceramide, human
leukocyte antigen (HLA)-DR, and glial fibrillary acidic pro-
tein (GFAP) (Table 2). All antibodies were diluted in
phosphate-buffered saline (PBS) supplemented with 1% bo-
vine serum albumin (BSA; Roche diagnostics GmbH, Man-
nhei, Germany). The sections were subsequently incubated
with Real EnVision HRP rabbit/mouse (Dako, Glostrup,
Denmark) for 30 min. Peroxidase labeling was visualized
using 3,3-diaminobenzidine (DAB) as chromogen (Dako,
Glostrup, Denmark). Nuclei were counterstained with
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hematoxylin. Finally, sections were dehydrated and mounted
using Entallan (Merck, Darmstadt, Germany) after which
they were analyzed with a light microscope (AXIO Scope
A1, Carl Zeiss, Germany).
For colocalization studies, sections were incubated for
30 min containing 10% normal goat serum. Subsequently,
sections were incubated overnight at 4 °C with primary
antibodies as indicated in Table 2. Alexa 488-labeled goat
anti-rabbit was used to detect ASM, CerS5, and CerS2
and Alexa 647-labeled goat anti-mouse was used to detect
ceramide (dilution 1:400, Life Technologies). Sections
were incubated for 1 h with their specific secondary anti-
body. Finally, sections were stained with Hoechst (dilution
1:1000, Molecular Probes) to visualize cellular nuclei and
mounted with Mowiol mounting medium. The represen-
tative images were taken using a Leica TCS SP8 confocal
laser-scanning microscope (Leica SP8, Mannheim,
Germany), 63× oil objective. Controls of the secondary
antibodies can be seen in Additional file 2.
Quantitative and correlation analysis
Quantitative and correlation analysis of the immunohis-
tochemical levels of ceramide, HLA-DR, GFAP, and
CerS5 was performed on the gray matter of the occipital
cortex of control, PDD, and FTD-Pi cases. Of each case,
four pictures spanning all cortical layers of the gray
matter of the inferior frontal gyrus were taken. The area
fraction of the DAB staining and double-fluorescent
staining was quantified using ImageJ version 1.52c.
Lipid extraction
Sphingolipids were analyzed as previously described [32,
34, 35]. Frozen fresh human brain samples were weighed
and homogenized in cold purified Millipore water (MQ,
18.2 MΩ cm) from a Milli-Q® PF Plus system (Millipore
B.V., Amsterdam, the Netherlands). Total lipids were ex-
tracted from brain homogenates by adding methanol
(MeOH), containing Cer-C17:0, Cer-C17:0/24:1, and
S1P-D7 (2, 2, 0.2 μg/ml in methanol, respectively, Avanti
Table 1 Summary of patient details
Patient # Age Gender PMD (h) Braak (lb) Cause of death
Control 1 79 M 06:30 1 CVA
Control 2 85 F 05:00 0 Multi organ failure
Control 3 85 F 04:40 1 Dehydration
Control 4 80 M 08:10 1 Unknown
Control 5 78 F 07:10 0 Euthanasia
PDD 1 80 F 04:15 4 CVA, dehydration
PDD 2 82 F 03:55 6 Dehydration, pneumonia
PDD 3 83 M 05:15 6 Pneumonia
PDD 4 81 M 05:50 5 Cachexia
PDD 5 84 M 06:30 4 Myocardial infarction
FTD-Pi 1 76 F 06:40 1 Cachexia
FTD-Pi 2 77 F 05:20 2 Complications 2nd to CVA
FTD-Pi 3 70 M 05:15 1 Aspiration pneumonia
FTD-Pi 4 70 M 06:40 1 Unknown
FTD-Pi 5 68 M 15:05 1 Aspiration pneumonia
PDD Parkinson’s disease dementia, FTD-Pi frontotemporal dementia Pick’s disease, PMD post-mortem delay, F female, M male
Table 2 Primary antibodies
Primary antibody Clone Dilution Species raised in Source
Ceramide MID 15B4 1:100 Mouse Alexis, Lausen, Switzerland [33]
ASM 1:200 Rabbit Santa Cruz, California, USA [33]
CerS5 1:500 Rabbit Abcam, Cambridge, UK
CerS2 1:500 Rabbit Abcam, Cambridge, UK
GFAP 1:2000 Rabbit DAKO, Glostrup, Denmark
LN3 1:500 Mouse VUmc, Amsterdam, The Netherlands
GFAP-Cy3 1:300 Mouse Sigma, MO, USA
LN3-Alexa 488 1:400 Mouse Vumc, Amsterdam, The Netherlands
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Polar Lipids) as internal standard, and 10% TEA solution
(trimethylamine (10/90, v/v) in MeOH/dichloromethane
(DCM) (50/50, v/v)). Samples were vortexed and
MeOH/DCM (50/50, v/v) was added. After 30 min at 4 °
C under constant agitation, samples were centrifuged at
14,000 rpm for 20 min at 4 °C. Supernatant was trans-
ferred to a glass vial, freeze-dried, and reconstituted in
MeOH before liquid chromatography-tandem mass
spectrometry (LC-MSMS).
Protein content
Protein content of all brain samples was determined by
bicinchoninic acid assay (Thermo Fisher Scientific,
Waltham, Massachusetts, USA) according to the manu-
facturer’s instructions. An 8-point calibration curve was
used to determine exact protein levels. Protein content
was used to normalize brain sphingolipid levels for
actual input.
LC-MSMS measurements
An autosampler (Shimadzu, Kyoto, Japan) injected 10 μL
lipid extracts into a Shimadzu HPLC system (Shimadzu)
equipped with a Kinetex C8 column (50 × 2.1 mm,
2.6 μm, Phenomenex, Maarssen, the Netherlands) at 30 °
C using a gradient, starting from 95% mobile phase A
(MQ/MeOH (50/50, v/v) containing 1.5 mM ammonium
formate and 0.1% formic acid) for 2 min and increased
to 93% mobile phase B (100% MeOH containing 1 mM
ammonium formate and 0.1% formic acid) at 5.5 min.
After 10 min, the column was flushed with 99% mobile
phase B for 2 min followed by a 2-min re-equilibration.
The flow rate was set at 0.25 ml/min with a total run
time of 14 min. The effluent was directed to a Sciex
Qtrap 5500 quadruple mass spectrometer (AB Sciex
Inc., Thornhill, Ontario, Canada) and analyzed in posi-
tive ion mode following electrospray ionization.
Nine-point calibration curves were constructed by plot-
ting area under the curve for each calibration standard
Cer-C14:0, Cer-C16:0, Cer-C18:0, Cer-C20:0, Cer-C22:0,
Cer-C24:1, Cer-C24:0, S1P, and SPH (Avanti polar lipids,
Alabaster, AL, USA) normalized to the internal standard.
Correlation coefficients (R2) obtained were > 0.999.
Sphingolipid concentrations were determined by fitting
the identified sphingolipid species to these standard
curves based on acyl-chain length. Instrument control and
quantitation of spectral data was performed using Analyst
1.4.2 and MultiQuant software (AB Sciex Inc.). Concen-
tration of sphingolipids is expressed as pmol/mg protein.
Real-time quantitative PCR
Human astrocytes of cortical origin, derived from fetal
material ranging from 18 to 21 weeks’ gestation, were
obtained from ScienCell (San Diego, CA USA) and
maintained in astrocyte medium (ScienCell, San Diego,
CA, USA). RNA was isolated using Trizol (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. mRNA concentrations were measured using
Nanodrop (Nanodrop Technologies, Wilmington, DE,
USA). cDNA was synthesized with the Reverse Tran-
scription System kit (Promega, Madison, WI, USA)
following manufacturer’s guidelines. Quantitative PCR
(qPCR) reactions were performed in the Viia7 sequence
detection system using the SYBR Green method
(Applied Biosystems, Foster City, CA, USA). All oligonu-
cleotides were synthesized by OcimumBiosolutions
(OcimumBiosolutions, IJsselstein, The Netherlands). The
primer sequence used is given in Table 3. Obtained
mRNA expression levels were normalized to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH).
Statistical analysis
Statistical analysis was performed using Graphpad Prism
software. Results are shown as mean with standard error
of the mean. The non-parametric Kruskal-Wallis
method with Dunn’s multiple comparison correction
was used. Pearson correlation coefficient was calculated
to evaluate the correlations between different variables.
Results
Neuroinflammation is associated with increased ceramide
levels in astrocytes in FTD Pick’s disease
We first examined the degree of neuroinflammation in
FTD-Pi, PDD, and non-demented control cases to con-
firm the expected difference in neuroinflammation be-
tween the three groups. Figure 1 shows a trend in
increasing activation of microglia between the different
Table 3 Primers used for RT-qPCR
Gene Forward primer Reverse primer
CerS1 ACGCTACGCTATACATGGACAC AGGAGGAGACGATGAGGATGAG
CerS2 CCGATTACCTGCTGGAGTCAG GGCGAAGACGATGAAGATGTTG
CerS4 CTTCGTGGCGGTCATCCTG TGTAACAGCAGCACCAGAGAG
CerS5 GCCATCGGAGGAATCAGGAC GCCAGCACTGTCGGATGTC
CerS6 GGGATCTTAGCCTGGTTCTGG GCCTCCTCCGTGTTCTTCAG
GAPDH CCATGTTCGTCATGGGTGTG GGTGCTAAGCAGTTGGTGGTG
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groups, where a significant difference (p = 0.0094) is
found between FTD-Pi and non-demented controls.
We next investigated the level of ceramide using immu-
nohistochemistry. Immunohistochemical analysis of the
brain sections in the gray matter revealed that specifically
astrocytes showed increased immunoreactivity for ceramide
(Fig. 2a). Quantification of ceramide immunoreactivity
indicated a significant difference between the three groups
(control: 0.58%, PDD: 1.25%, FTD-Pi: 3.65%, p = 0.0029).
Post-hoc analysis showed a significant increase exclusively
in the percentage of immunopositive areas for ceramide in
FTD-Pi pathological cases compared with non-demented
controls (p = 0.0047) (Fig. 2b).
To support the correlation between increased immunore-
activity for ceramide in astrocytes, we compared the immu-
noreactive levels of ceramide with an astrocytic marker
(GFAP). This analysis showed a significant correlation
between the expression of ceramide and GFAP (Pearson’s
r = 0.7, p= 0.003) (Fig. 2c). Moreover, double immunofluor-
escent labeling confirmed that ceramide is specific for
astrocytes (Fig. 3a) and not microglia (Fig. 4). In addition,
the level of ceramide in astrocytes is significantly increased,
independent of the number of astrocytes, in FTD-Pi
compared to non-demented controls (p= 0.0037) (Fig. 3b).
The level of ceramide in astrocytes is not regulated by
acid sphingomyelinase
To gain more insight into the pathway that is responsible
for the increase in ceramide observed in astrocytes, we ex-
amined the expression of the ceramide synthesizing enzyme
acid sphingomyelinase (ASM) in the cortex of PDD,
FTD-Pi, and non-demented age-matched controls. Immu-
nohistochemical analysis revealed a heterogeneous image
where mainly microglia showed immunoreactivity for ASM
but also neurons and astrocytes, albeit to a lesser extent
(Fig. 5a). The overall quantification of ASM expression did
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Fig. 1 Increased activation of microglia in FTD-Pi. Quantitative
analysis of the immunoreactive area for microglia (HLA-DR) in
control (n = 5), PDD (n = 5), and FTD-Pi (n = 5). The values represent
the mean ± S.E.M. Statistical significance (Kruskal-Wallis test, with
Dunn’s multiple correction) indicated with asterisks: **p < 0.01
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Fig. 2 Increased levels of ceramide in FTD-Pi. a Immunohistochemical staining for ceramide in the inferior frontal gyrus of non-demented
controls, PDD, and FTD-Pi. DAB (brown) was used as chromogen and hematoxylin (blue) was used for counterstaining of the nucleus. White
arrows indicate astrocytes. Bar: 50 μm. b Quantitative analysis of the immunoreactive area for ceramide in FTD-Pi (n = 5), PDD (n = 5), and controls
(n = 5). The values represent the mean ± S.E.M. c Correlation analysis of the immunoreactivity levels of ceramide with astrocytes (GFAP). Statistical
significance (Kruskal-Wallis test, with Dunn’s multiple correction) indicated with asterisks: **p < 0.01
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not show a significant difference between the three groups
(control: 0.79%, PDD: 0.81%, FTD-Pi: 1.93%, p = 0.072)
(Fig. 5b).
The expression of ceramide synthase 5 in astrocytes
correlates with the increase in ceramide
Next, we examined whether an altered regulation of cer-
amide synthases might be responsible for the observed
enhanced ceramide levels in astrocytes. To investigate
which CerS are expressed by astrocytes, we performed
qPCR on isolated primary human astrocytes. Figure 6a
shows that human astrocytes mainly express mRNA
transcripts encoding for CerS2 and CerS5. Subsequent
immunohistochemical analysis of the gray matter of
PDD, FTD-Pi, and non-demented control cases revealed
that CerS2 is predominantly expressed around the nuclei
of different cell types, including astrocytes. However,
CerS2 expression did not colocalize with GFAP or with
ceramide (Fig. 6b). In contrast, immunohistochemical
analysis of the gray matter of PDD, FTD-Pi, and
non-demented control cases showed that predominantly
reactive astrocytes express CerS5. Moreover, the CerS5
expression in astrocytes colocalized with ceramide
(Fig. 6c). In addition, by quantifying the expression level
of CerS5 in astrocytes using double immunofluorescent
labeling, we were able to find a positive correlation be-
tween the immunoreactive ceramide levels and CerS5
expressed in reactive astrocytes (R = 0.54, p = 0.039)
(Fig. 6d). Interestingly, the overall expression of CerS5 in
the gray matter, independent of cell type, showed a sig-
nificant increase in FTD-Pi compared to non-demented
controls (p = 0.015)(Fig. 6e).
C16:0 ceramide is increased under neuroinflammatory
conditions in FTD Pick’s disease
Finally, we investigated the ceramide content in
post-mortem tissues of patients with PDD and FTD-Pi
compared to non-demented controls using HPLC MS/
MS to gain more insight in the alterations of the differ-
ent ceramide species. Total ceramide content was not
significantly different between the three groups
(controls = 17,891 ± 1776, PDD = 16,376 ± 1626, and
FTD-Pi = 19,644 ± 2748, p = 0.566). In order to com-
pare the distribution of ceramide fatty acyl chains in
the control, PDD, and FTD-Pi samples, data were
expressed as a percentage of total ceramide content
(Fig. 7a). Importantly, this analysis revealed a significant
increase in C16:0 acyl chain content (p = 0.0116) ac-
companied by a significant decrease in C24:1 acyl chain
content (p = 0.0392) in FTD-Pi compared to non-de-
mented controls. To obtain a complete overview of the
sphingolipid rheostat, we measured sphingosine and
S1P as well (Fig. 7b, c). However, no significant differ-
ences were found for the detected levels of sphingosine
and S1P between FTD-Pi, PDD, and non-demented
controls.
BA
Fig. 3 Increased levels of ceramide in specifically astrocytes in FTD-Pi. Colocalization studies indicated that a ceramide containing cells (green)
were immunopositive for GFAP (red), indicative of astrocytes. Nuclei were counterstained with Hoechst (blue). Bar: 20 μm. b Quantitative analysis
of the fluorescent intensity of ceramide in astrocytes in control (n = 5), PDD (n = 5), and FTD-Pi (n = 5). The values represent the mean ± S.E.M.
Statistical significance (Kruskal-Wallis test, with Dunn’s multiple correction) indicated with asterisks: **p < 0.01
Fig. 4 Ceramide does not colocalize with microglia. Colocalization
studies indicated that ceramide containing cells (red) were not
immunopositive for HLA-DR (green), indicative for microglia. Nuclei
were counterstained with Hoechst (blue). Bar: 20 μm
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Discussion
In this pathological study, we set out to investigate
whether increased pro-apoptotic ceramide is a common
denominator of neuroinflammation in two different
types of neurodegenerative diseases. The present study
indicates that predominantly astrocytes show increased
levels of ceramide under neuroinflammatory conditions
in FTD Pick’s disease. When investigating the machinery
responsible for ceramide production, no differences in
the expression of ASM nor CerS2 was found, while on
the other hand a positive correlation between the ex-
pression of CerS5 and ceramide in astrocytes was ob-
served. In line with these results, a significant increase
in C16:0 ceramide was observed in post-mortem tissues
of FTD-Pi cases compared to non-demented controls.
Previous studies from our lab and others already indi-
cated enhanced production of ceramide by reactive as-
trocytes in multiple sclerosis, Alzheimer’s disease (AD),
and AD with capillary cerebral amyloid angiopathy, dis-
eases which are all characterized by various levels of
A B
Fig. 5 ASM expression is not specific for astrocytes. a Immunohistochemical staining for ASM in the inferior frontal gyrus of non-demented
controls, PDD, and FTD-Pi. DAB (brown) was used as chromogen and hematoxylin (blue) was used for counterstaining of the nucleus. Black
arrows indicate microglia. White arrows indicate astrocytes. Bar: 50 μm. b Quantitative analysis of the immunoreactive area for ASM in FTD-Pi
(n = 4), PDD (n = 5), and controls (n = 5). The values represent the mean ± S.E.M
20 40 60 80 10
0
-2
0
2
4
6
8
Co
nt
ro
l
PD
D
FT
D-
Pi
0
1000
2000
3000
4000
Ce
rS
1
Ce
rS
2
Ce
rS
4
Ce
rS
5
Ce
rS
6
0.00
0.02
0.04
0.06
CerS in Astrocytes
R
el
at
iv
e
m
R
N
A
ex
p
re
ss
io
n
C
er
am
id
e 
im
m
u
n
o
re
ac
ti
vi
ty
CerS5 immunoreactivity
O
ve
ra
ll 
C
er
S
5 
(A
U
)
FTD-Pi
PDD
Control
*
R = 0.54
p = 0.039
CerS2 Ceramide Hoechst Overlap
A
B C
D E
CerS5 Ceramide Hoechst Overlap
Fig. 6 The expression of ceramide synthase 5, and not 2, in astrocytes correlates with the increase of ceramide in astrocytes. a The relative
abundance normalized to GAPDH of the different CerSs in astrocytes where CerS2 and CerS5 relative mRNA expression are the highest. b
Immunofluorescent double labeling of CerS2 (green) and ceramide (red) shows no colocalization, whereas c CerS5 (green) does colocalize with
ceramide (red). Nuclei were counterstained with Hoechst (gray). Bar: 20 μm. d Correlation analysis of the immunoreactivity levels of ceramide
with CerS5 expressed in astrocytes. e Quantitative analysis of CerS5 in control (n = 5), PDD (n = 5), and FTD-Pi (n = 5). The values represent the
mean ± S.E.M, *p < 0.05
de Wit et al. Journal of Neuroinflammation           (2019) 16:48 Page 7 of 11
neuroinflammation [32, 33, 36]. Taken together, these re-
sults are suggesting that ceramide in reactive astrocytes
is a possible indicator of neuroinflammation, despite the
varying underlying causes of the diseases.
We further investigated the expression of relevant en-
zymes in sphingolipid biology that are implicated as me-
diators in the cell stress response and intimately linked
to inflammation [37, 38]. Unexpectedly, our data sug-
gests that the observed ceramide production in reactive
astrocytes is independent of enhanced levels of ASM. In-
deed, both ASM and nSMase can act on sphingomyelin
to generate ceramide. For instance, it has been shown
that nSMase activity in astrocytes is quickly upregulated
after cerebral ischemia [39]. However, astrocytes isolated
from multiple sclerosis lesions showed increased mRNA
expression of ASM linked to increased ceramide levels
[33]. Therefore, the activation of the different sphingo-
myelinases seems to depend on disease-specific stimuli.
Interestingly, our results indicate for the first time that
the increase in the expression of CerS5, the enzyme
mainly responsible for the generation of C16:0 ceramide,
correlates with ceramide production in astrocytes. In
contrast, no correlation nor colocalization of CerS2
(main producer of C24:0 ceramide) with ceramide in re-
active astrocytes was found, suggesting the ceramide in
reactive astrocytes to be C16:0 ceramide and not C24:0
ceramide. Although CerS5 has been extensively studied
due to its ability to synthesize C16:0 ceramide, these
studies are not performed in the brain and are not
addressing its role in neurodegenerative disorders [38,
40, 41]. So far, only a few studies describe the expression
of CerS genes in the brain. However, most of them are
either focused on different CerSs, performed in mouse
brain, or are limited to analyses of their mRNA levels
[42–45]. Importantly, since CerS5 is closely related to
CerS6 and shows a very high extent of amino acid
sequence identity, we cannot exclude the involvement of
CerS6. These two enzymes share their substrate specifi-
city for C16:0 acyl-CoA and are similar in their expres-
sion pattern [46]. Therefore, future studies are needed to
identify the importance of CerS5 as ceramide-producing
enzyme in astrocytes.
The correlation of CerS5 with ceramide in astrocytes
is further supported by the detected increase in levels of
C16:0 ceramide in FTD-Pi using HPLC MS/MS analysis
of the brain homogenates. Considering that our data
show that sphingosine and S1P levels do not differ be-
tween FTD-Pi and PDD compared to non-demented
controls, our findings suggests that the increase of C16:0
ceramide is a result of ceramide accumulation instead of
decreased ceramide breakdown. Moreover, the levels of
C16:0 ceramide are inversely correlated to levels of
C24:1 ceramide, indicating a shift to a more pro-apop-
totic environment. It has become apparent that the dif-
ferent lengths of the fatty acids of ceramide exert a
variety of distinct functions, where for instance C16:0
ceramide has been suggested to be the dominant species
elevated during apoptosis [47–49]. Several studies
related to cancer report opposing effects of the
long-chain ceramides (C14:0–C20:0) compared to the
very-long-chain ceramides (C22:0–C26:0), where a shift
from very-long to long-chain ceramides increases apop-
tosis, suggesting the equilibrium between the chain
lengths of ceramides is regulating cell death [50, 51].
However, the direct association found in these studies
cannot be concluded from our results since these studies
were performed in cell lines, whereas our HPLC MS/MS
measurements include whole brain tissue homogenates,
A B
C
Fig. 7 Altered ceramide levels in FTD-Pi compared to controls. a Levels of ceramides of different chain-lengths, b sphingosine, and c S1P were
quantified by use of HPLC MS/MS in brain homogenates of FTD-Pi (n = 5), PDD (n = 5), and controls (n = 5). Data show the mean percentage ±
S.E.M. Statistical significance between groups (Kruskal-Wallis test, with Dunn’s multiple correction) is indicated with asterisk: *p < 0.05
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comprising different cell types. Therefore, we can only
conclude that the sphingolipid balance is altered but
cannot yet pinpoint which cell type(s) are responsible
for this change.
The increased ceramide levels in astrocytes might
serve as a possible therapeutic target to limit ongoing
neuroinflammation. Not only ceramide but also the
ceramide-derived glycosphingolipid lactosylceramide in
astrocytes is increased during chronic CNS inflamma-
tion and promotes inflammation and neurodegeneration
[52]. Moreover, ceramide can be secreted by astrocytes
and subsequently affect neighboring cells, possibly acting
as a mediator for neuronal apoptosis [53, 54]. Upon acti-
vation, astrocytes show an upregulation of the
sphingosine-1-phospate receptor 3 (S1P3) in different
neurodegenerative diseases [32, 55]. It has been shown
that S1P3 is a target of Fingolimod, a synthetic analog of
S1P, which is approved as an oral treatment for
relapsing-remitting multiple sclerosis [56]. Previous
studies indicate that Fingolimod administration reduces
ceramide formation in reactive astrocytes [33]. In
addition, the secreted ceramide might also act as a pos-
sible biomarker for neuroinflammation in neurodegener-
ative disorders. For instance, in the cerebral spinal fluid
of patients with MS, an increase in certain ceramide spe-
cies was found [57]. Also, studies are ongoing to identify
individuals at increased risk of cognitive impairment by
characterizing distinct plasma ceramides profiles. Inter-
estingly, promising preliminary results showed increased
C16:0 levels in plasma of PDD patients, indicating a pos-
sible predictive value for ceramide [13].
Importantly, there are some limitations to our study,
such as the relatively low number of unique well-charac-
terized cases, which renders caution in the interpretation
of the data. However, through the combination of a var-
iety of validated methods, we were still able to demon-
strate significant differences between the different
groups. Inclusion of more cases may reduce the chance
of a type 2 error, but having found an effect, albeit the
limited statistical power, makes us confident on the rele-
vance of our data. In addition, although PDD as an
intermediate group did show a trend in all our results,
increasing the number might push it to significance.
Also, the isolation of astrocytes was not possible with
our tissue, hence we can only speculate about the in-
crease of C16:0 ceramide as the product of CerS5 in
astrocytes. Therefore, the identification of CerS5 as
possible initiator of the production of C16:0 ceramide
in astrocytes would benefit from an additional mechan-
istic study.
Conclusion
In conclusion, the present results suggest that astrocytic
ceramide is closely associated with the neuroinflammatory
process. Importantly, we identified CerS5 as possible me-
diator of C16:0 ceramide in astrocytes in the human brain.
While only a relatively small sample size was feasible in
this study, the significant differences that were found in
the sphingolipid balance between the groups provide use-
ful avenues for further research and possible future treat-
ments, based on modifying the sphingolipid pathway.
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